Vera Therapeutics to file TRUTAKNA sBLA with FDA in Q4 2026
Vera Therapeutics said it will file an sBLA for TRUTAKNA with the FDA in Q4 2026, targeting 2027 approval. The company cited early commercial momentum, with shares up about 2% to ~$34.76.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.